Turn Therapeutics (TTRX) Stock News
$TTRX · NASDAQ · 1 stories in 30 daysBORSA has published 1 story on Turn Therapeutics (TTRX) in the past 30 days. BORSA’s news read on TTRX is balanced at 50/100, based on 1 company event over the past 7 days. Turn Therapeutics’ next earnings report is scheduled for Thursday, Nov 12.
The wire on $TTRX
newest first · updated · direct subject stories onlyTurn Therapeutics (TTRX) announced its CEO and clinical lead will participate in a U.S. Bancorp | BTIG virtual fireside chat on October 28 at 10:00 AM ET. The discussion will cover the company's strategy for developing GX-03 in atopic dermatitis. The event is for institutional clients.
neutral 50 · impact 10The wire on this name is open. What the tape did about it is one free account away.
One free account opens every story complete, the live board and the 30-day calendar, and 3 complete ticker and report views a day. No card. The wire stays free to read.
Turn Therapeutics (TTRX) stock: common questions
What is the latest Turn Therapeutics stock news?
The highest-impact TTRX story BORSA published in the past 30 days:
· Turn Therapeutics CEO and Clinical Lead to join BTIG fireside chat on atopic dermatitis strategy